Literature DB >> 22797189

Rituximab in membranous nephropathy: is it a first-line treatment?

Gerald B Appel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22797189     DOI： 10.1681/ASN.2012060602

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  5 in total

Review 1.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

2.  Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Ina Thiele; Gunther Zahner; Ulf Panzer; Sigrid Harendza; Rolf A K Stahl
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

Review 3.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

Review 4.  Primary glomerulonephritis: A review of important recent discoveries.

Authors:  Jürgen Floege
Journal:  Kidney Res Clin Pract       Date:  2013-07-26

5.  Treatment with rituximab in idiopathic membranous nephropathy.

Authors:  Marco Fiorentino; Francesco Tondolo; Francesca Bruno; Barbara Infante; Giuseppe Grandaliano; Loreto Gesualdo; Carlo Manno
Journal:  Clin Kidney J       Date:  2016-10-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.